FORWARD PHARMA A/S
CVR 28865880 · Public limited company (A/S) · Dissolved after voluntary liquidation
FORWARD PHARMA A/S is a Public limited company (A/S), founded on , based in Hellerup. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company is no longer active (status: dissolved after voluntary liquidation). 19 annual reports have been published, of which 1 more than six months after the end of the financial year. The latest annual report (31 Dec 2023) shows equity of DKK 426.4m and a net result of DKK -3.8m.
Company details
- CVR number
- 28865880
- Status
- Dissolved after voluntary liquidation
- Company type
- Public limited company (A/S)
- Founded
- Ceased
- Address
- Strandvejen 125
2900 Hellerup - Municipality
- København
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 1.0m
- Employees
- 4 (2018)
- Auditor
- PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 1 of 18 |
| Missing annual report | No |
| Negative equity | No |
| Equity ratio | 60.5% |
| Current ratio | 153% |
| Moves (last 2 years) | 1 |
| CEO changes in total | 13 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 114 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2023 | 2022 |
|---|---|---|
| Gross profit | DKK -6.1m | DKK -11.6m |
| Net profit | DKK -3.8m | DKK -31.5m |
| Equity | DKK 426.4m | DKK 430.4m |
| Total assets | DKK 704.7m | DKK 529.9m |
| Cash | DKK 42.6m | – |
| Short-term debt | DKK 278.2m | – |
| Avg. employees | 2 | – |
Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2024 – 31 Dec 2024 | 136 | ||
| 1 Jan 2023 – 31 Dec 2023 | 182 | ||
| 1 Jan 2022 – 31 Dec 2022 | 164 | ||
| 1 Jan 2021 – 31 Dec 2021 | 152 | ||
| 1 Jan 2020 – 31 Dec 2020 | 153 | ||
| 1 Jan 2019 – 31 Dec 2019 | 168 | ||
| 1 Jan 2018 – 31 Dec 2018 | 134 | ||
| 1 Jan 2017 – 31 Dec 2017 | 151 | ||
| 1 Jan 2016 – 31 Dec 2016 | 130 | ||
| 1 Jan 2015 – 31 Dec 2015 | 133 | ||
| 1 Jan 2014 – 31 Dec 2014 | 119 | ||
| 1 Jan 2013 – 31 Dec 2013 | 167 | ||
| 1 Jan 2012 – 31 Dec 2012 | 160 | ||
| 1 Jan 2011 – 31 Dec 2011 | 186 | Late | |
| 1 Jan 2010 – 31 Dec 2010 | 153 | ||
| 1 Jan 2009 – 31 Dec 2009 | 122 | ||
| 1 Jan 2008 – 31 Dec 2008 | 125 | ||
| 1 Jan 2007 – 31 Dec 2007 | 128 | ||
| 1 Jul 2005 – 31 Dec 2006 | 155 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Morten Priskorn | ||
| CEO | Lars Folke Henrik Nilsson | ||
| CEO | Morten Priskorn | ||
| CEO | Peder Møller Andersen | ||
| CEO | Joel David Sendek | ||
| CEO | Joel David Sendek | ||
| CEO | Rupert Sandbrink | ||
| CEO | Claus Bo Søndergaard Svendsen | ||
| Board | Christian Karsten Hansen | ||
| Board | Florian Schønharting | ||
| Board | Marianne Kock | ||
| Board | Lars Folke Henrik Nilsson | ||
| Board | Torsten Goesch | ||
| Board | Hans Thalsgård Schambye | ||
| Board | Wyle David Solomon | ||
| Board | Florian Schønharting | ||
| Board | John Kevin Buchi | ||
| Board | Johannes Gerardus Joseph van de Winkel | ||
| Board | Jakob Mosegaard Larsen | ||
| Board | Grant Hellier Lawrence | ||
| Board | Duncan Moore | ||
| Board | Karen Lesley Smith | ||
| Owner (20%) | NORDIC BIOTECH K/S | ||
| Owner (5%) | NB FP INVESTMENT K/S | ||
| Owner (15%) | Rosetta Capital I, LP | ||
| Owner (20%) | NORDIC BIOTECH OPPORTUNITY FUND K/S | ||
| Owner (20%) | The Bank of New York Mellon | ||
| Owner (90%) | BNY (Nominees) Limited (as nominee of The Bank of New York Mellon) | ||
| Owner (10%) | GEP II, L.P. | ||
| Owner (20%) | NORDIC BIOTECH K/S | ||
| Owner (20%) | NORDIC BIOTECH OPPORTUNITY FUND K/S | ||
| Owner (10%) | BNY (Nominees) Limited (as nominee of The Bank of New York Mellon) | ||
| Owner (5%) | BNY (Nominees) Limited (as nominee of The Bank of New York Mellon) | ||
| Owner (5%) | Mason Capital Master Fund, L.P. | ||
| Owner (5%) | FORWARD PHARMA A/S | ||
| Owner (5%) | Nerine Trust Company Limited | ||
| Auditor | EY Danmark A/S | ||
| Auditor | ERNST & YOUNG DENMARK P/S | ||
| Auditor | EY Godkendt Revisionspartnerselskab | ||
| Auditor | PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB | ||
| Founder | NORDIC BIOTECH K/S |
The CEOs' other companies
Morten Priskorn – 3 other companies
- Krudtmøllen I ApS Active
- NTG Nordic Transport Group A/S Active
- Neumirna Therapeutics ApS Active
Lars Folke Henrik Nilsson – 3 other companies
- HYSCITE DISCOVERY A/S Compulsorily dissolved
- MEDLEAP ApS Opløst
- OSTEOLOGIX ApS Opløst
Peder Møller Andersen – 9 other companies, of which 2 bankrupt
- ApS VED KLÆDEBO 12. HØRSHOLM Bankrupt 12 Dec 2003
- K/S VED KLÆDEBO 12. HØRSHOLM Bankrupt 12 Dec 2003
- ACTAVIS A/S Fusioneret
- AP PHARMA EXCHANGE A/S Opløst
- ECOMED ApS Opløst
- FRED CONSULTING ApS Fusioneret
- FRED MANAGEMENT ApS Active
- FREEDOM MANAGEMENT & INVEST ApS Opløst
- UNP2 A/S Fusioneret
Claus Bo Søndergaard Svendsen – 4 other companies
- FWP HoldCo ApS Opløst
- Forward Pharma FA ApS Opløst
- S21 Advisory ApS Opløst
- S21 Holding ApS Active
Address history (3 moves)
| Strandvejen 125, 2900 Hellerup | |
| Østergade 24A, 1., 1100 København K | |
| Nyhavn 43B, 2., 1051 København K | |
| Østergade 5, 3., 1100 København K |
Employees per year
Other companies at the same address
- E & S - Consult IVS Bankrupt
- Redline Media Group ApS Bankrupt
- VIA Telegroup Danmark ApS Bankrupt
- AL Copenhagen A/S Active
- AP Management ApS Active
- AarhusGeoSoftware ApS Opløst
- Administrationsselskabet i "Buen" ApS Active
- Andersen & Friends Holding ApS Active
- BAKKEDAL INVEST ApS Opløst
- BESTYRELSESPOSTEN ApS Opløst
- BIOGEN (DENMARK) A/S Active
- Biofuel Technology Holding ApS Active
- Borderless Denmark Holdings ApS Active
- CAPNORDIC HOLDING ApS Active
- CKIT HOLDING ApS Active
- CKIT Software ApS Opløst
- COHAMI HOLDING ApS Opløst
- CREDITSAFE DENMARK ApS Active
- Clarify Commerce ApS Active
- Classic Maritime ApS Active
- CoreWeave SVL01 ApS Active
- Crone Burmeister Adv. ApS Active
- CyberOne ApS Active
- Dansk Demetra ApS Active
- Davy DebtCo ApS Active
Similar companies in København
- AffiCon ApS Valby
- EXTITUTION ApS København Ø
- Coco Sense ApS København NV
- Everllence Denmark A/S København SV
- BioSpectre ApS København V
- Nordic Cell Therapy Group ApS København N
- FiberSure ApS København Ø
- Tasira ApS København N
- Xenogen ApS København S
- Magnalev Core ApS København SV
- Pin Joint ApS København S
- Maglya ApS København Ø
Questions and answers about FORWARD PHARMA A/S
Has FORWARD PHARMA A/S gone bankrupt?
No, FORWARD PHARMA A/S is not registered as bankrupt in the CVR register. Its status is: dissolved after voluntary liquidation.
Who is the auditor of FORWARD PHARMA A/S?
FORWARD PHARMA A/S most recently used PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab.
When was FORWARD PHARMA A/S founded?
FORWARD PHARMA A/S was founded on 1 July 2005.
What is the equity of FORWARD PHARMA A/S?
Equity was DKK 426.4m according to the annual report for the period ending 31 December 2023.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.